Actively Recruiting
Characterization and Phenotyping of Patients Who Are Offered Drug Therapy for Obesity
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2026-02-17
500
Participants Needed
1
Research Sites
557 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is multicenter and observational, consisting of a cross-sectional phase (V0) in which data will be collected from patients who are offered drug therapy, and a prospective longitudinal phase in which only patients who agree to start drug therapy for obesity will be involved
CONDITIONS
Official Title
Characterization and Phenotyping of Patients Who Are Offered Drug Therapy for Obesity
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 12 years or older
- Therapeutic indication for treatment with one of the following obesity drugs: Orlistat, Naltrexone/Bupropion (Mysimba�ae), Liraglutide (Saxenda�ae), Semaglutide (Wegovy�ae), Tirzepatide (Mounjaro�ae)
You will not qualify if you...
- Type 1 or type 2 diabetes mellitus
- Secondary forms of obesity, including:
- Hypothalamic obesity (monogenic and acquired forms)
- Syndromic obesity (e.g., Prader-Willi, Alstrom, Bardet Biedl)
- Endocrinopathies associated with obesity such as Cushing's syndrome and uncompensated hypothyroidism
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, Italy, 40138
Actively Recruiting
Research Team
U
Uberto Pagotto, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here